Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of QX005N injection in adults with prurigo nodularis
ChiCTR2200066243Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QX005N in prurigo nodularis (PN) (4 arms), sponsored by Peking University People's Hospital. Primary endpoint: Percentage of participants with at least 4-point improvement in WI-NRS from baseline. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
QX005N
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on ChiCTR2200066243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066243.